Hua-Jun Chen1 article listing Hua-Jun Chen in Nature Communications, indexed by Paperzzz from Crossref and OSF.Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) Nature Communications